Gemcitabine/ clindamycin
Phase 3Small molecule
Gemcitabine/ clindamycin is one of 13 small molecule programs targeting Ventral Hernia. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Ventral Hernia
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
Robaxin
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Xylocaine
CCitius Pharmaceuticals, Inc.
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Gemcitabine/ clindamycin
PPrisma Health-Upstate
Phase 3
MOA-728
BBausch Health Americas, Inc.
Phase 3
AGN-151607-DP
AbbViePhase 2
Entereg
Merck & Co.Preclinical
CA-008
CConcentric Analgesics
Phase 2
BOTOX Dose B
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gemcitabine/ clindamycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPrisma Health-Upstate